BBOT

BridgeBio Oncology Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company headquartered in South San Francisco, California, specializing in the development of targeted small molecule inhibitors for diverse cancer indications. Leveraging a robust drug discovery platform, the company is committed to creating precision medicine solutions that address significant unmet medical needs in oncology. With a well-defined pipeline comprising therapeutics at various stages of development, BridgeBio is strategically oriented towards identifying and targeting specific genetic drivers of cancer, thereby enhancing treatment efficacy and improving patient outcomes in the oncology landscape.